title: Filamin A mutant lacking actin-binding domain restores mu opioid receptor regulation in melanoma cells.
abstract: We have previously reported that the protein filamin A (FLA) binds to the carboxyl tail of the mu opioid receptor (MOPr). Using human melanoma cells, which do not express filamin A, we showed that receptor down-regulation, functional desensitization and trafficking are deficient in the absence of FLA (Onoprishvili et al. Mol Pharmacol 64:1092-1100, 2003). Since FLA has a binding domain for actin and is a member of the family of actin cytoskeleton proteins, it is usually assumed that FLA functions via the actin cytoskeleton. We decided to test this hypothesis by preparing cDNA coding for mutant FLA lacking the actin binding domain (FLA-ABD) and expressing FLA-ABD in the human melanoma cell line M2 (M2-ABD cell line). We report here that this mutant is capable of restoring almost as well as full length FLA the down-regulation of the human MOPr. It is similarly very effective in restoring functional desensitization of MOPr, as assessed by the decrease in G-protein activation after chronic exposure of M2-ABD cells to the mu agonist DAMGO. We also found that A7 cells, expressing wild type FLA, exhibit rapid activation of the MAP kinases, ERK 1 and 2, by DAMGO, as shown by a rise in the level of phospho-ERK 1 and 2. This is followed by rapid dephosphorylation (inactivation), which reaches basal level between 30 and 60 min after DAMGO treatment. M2 cells show normal activation of ERK 1 and 2 in the presence of DAMGO, but very slow inactivation. The rapid rate of MAPK inactivation is partially restored by FLA-ABD. We conclude that some functions of FLA do not act via the actin cytoskeleton. It is likely that other functions, not studied here, may require functional binding of the MOPr-FLA complex to actin.
authors.affiliation: Department of Psychiatry, New York University School of Medicine, 550 First Avenue, New York, NY 10016, USA.
authors.forename: Irma
authors.initials: I
authors.lastname: Onoprishvili
authors.forename: Solav
authors.initials: S
authors.lastname: Ali
authors.forename: Matthew L
authors.initials: ML
authors.lastname: Andria
authors.forename: Adam
authors.initials: A
authors.lastname: Shpigel
authors.forename: Eric J
authors.initials: EJ
authors.lastname: Simon
mesh_terms: D000199:Actins / Q000378:metabolism; D045744:Cell Line, Tumor; D003285:Contractile Proteins / Q000235:genetics* / Q000502:physiology*; D015536:Down-Regulation; D020875:Enkephalin, Ala(2)-MePhe(4)-Gly(5)- / Q000494:pharmacology; D004789:Enzyme Activation; D064448:Filamins; D006801:Humans; D008545:Melanoma / Q000378:metabolism*; D008840:Microfilament Proteins / Q000235:genetics* / Q000502:physiology*; D019950:Mitogen-Activated Protein Kinase 1 / Q000378:metabolism; D048052:Mitogen-Activated Protein Kinase 3 / Q000378:metabolism; D010766:Phosphorylation; D011485:Protein Binding; D017434:Protein Structure, Tertiary; D017450:Receptors, Opioid, mu / Q000378:metabolism*
chemical_list: D000199:Actins; D003285:Contractile Proteins; D064448:Filamins; D008840:Microfilament Proteins; D017450:Receptors, Opioid, mu; D020875:Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; D019950:Mitogen-Activated Protein Kinase 1; D048052:Mitogen-Activated Protein Kinase 3